Background Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis that will develop in 7-40 percent of patients with psoriasis. PsA is one of the spondyloarthropathies that can have differantiate clinical manifestations such as oligoarticular and polyarticular peripheral arthritis. Many studies indicate that PsA is associated with hypertension, obesity, hyperlipidemia, diabetes mellitus, metabolic syndrome (MetS) and cardiovascular diseases (CVD).
Objectives Some authors claim that the prevalence of these comorbidities is higher in PsA compared with psoriasis without arthritis patients. We aimed to identify the prevalence of MetS and CVD risk in patients with PsA.
Methods We performed a restrospective hospital based-case-control study on 102 adult patients with PsA (72 female, 30 male, mean age: 44±11,6) who fulfilled CASPAR criteria and 102 control patients with rheumatoid arthritis (RA) (76 female, 26 male, mean age: 47±11,6) who fulfilled EULAR-ACR criteria. MetS was diagnosed by NCEP ATP III and IDF criteria. The 10-year CVD and CHD risk score was calculated by Framingham risk score (http://www.framinghamheartstudy.org/risk).
Results Prevalence of MetS was higher in PsA patients compared with RA patients according to the NCEP ATP III (p:0.019) and IDF criteria (p:0.05) But there was no significant difference between the two groups regarding to the 10-year CVD (p:0.333) and CHD (p:0.798) risk. There was no significant difference between clinical subtypes of PsA with regard to metabolic syndrome (p:0.229). Despite the prevalence of MetS was higher in female PsA patients (p:0.009), there was no difference between gender in control group (p:0.240). Significantly increased prevalence of hypertriglyceridemia was determined in PsA patients (p:0.019). Despite PsA patients had lower mean HDL levels (p:0.047), this difference was not significant according to the MetS diagnosis criteria. In control group, the prevalence of CVD risk and smoking habit was higher in male patients (p:0.003 via p<0.001).
Conclusions In this study, we have found increased MetS prevalence in PsA compared with RA patients. Two groups had similar risk of CVD and CHD. As compared with population based studies, MetS frequency was higher in PsA patients. Our results and the similar studies in the literature indicate that the frequency of MetS and CVD/CAD in PsA was significantly higher than RA. For this reason, prevention and control guidelines of RA for these comorbidities can be used in PsA patients, until the development of PsA guideline.
Disclosure of Interest None declared